The event is an Analysts/Investors Earning Call hosted by 'Systematix Institutional Equities' to discuss the financial performance/results for Q2 and half year ended September 30, 2026.
The call is scheduled for Tuesday, November 17, 2026 at 4:30 PM IST.
The stated purpose is to discuss the financial performance/financial results of the Company for Quarter-II and half year ended September 30, 2026.
The meeting is scheduled after the earnings announcement, as it references a previous intimation of a Board Meeting dated November 11, 2026.
Management participants include: Mr. Manish Dhanuka (Managing Director), Mr. Mridul Dhanuka (Whole Time Director), and Mr. Sunil Kumar Gupta (Chief Financial Officer).
The information regarding the call will be hosted on the Company's website at www.orchidpharma.com.
The company has included a note stating that the schedule may change due to exigencies on the part of the Analysts/Investors/Company.
The document includes an enclosed invite for the earnings call but does not explicitly state that a presentation, deck, transcript, or recording will be made available.
The disclosure is made pursuant to SEBI regulations, indicating standard compliance, but it does not contain an explicit statement that no unpublished price sensitive information (UPSI) will be shared.
Additional Notes Section
An attachment was included with the disclosure: the invite for the Analysts/Investors Earnings Call.
No financial data or performance figures were disclosed in this announcement.
The document provides detailed dial-in numbers and toll-free numbers for various locations (India, USA, UK, Singapore, Hong Kong) and a Diamond Pass registration link for direct access, but these are considered operational logistics.
The intimation is signed by Kapil Dayya, Company Secretary & Compliance Officer (Membership No. F10698).
